Securities issued under LR7.1 & LR7.1A

16 May 2023 – Perth, Australia: PharmAust Limited (ASX:PAA & PAAO) refers to the announcement released on 3 May 2023 titled "PharmAust Raises $2.5m via Placement" and the associated Appendices 3B, 3G and 2A. The Company advises that securities were issued utilising Listing Rule 7.1 and Listing Rule 7.1A as per the following table:

	LR7.1 capacity	LR7.1A capacity
Issue of Placement Shares	29,244,294	755,706
Issue of attaching options	15,000,006	
Adviser Options to Baker Young Ltd	2,730,000	
Adviser Shares to Spark Plus	562,557	

This announcement is authorised by Sam Wright on behalf of the Board of Directors.

Enquiries:

Anusha Aubert
Investor Relations
investorenquiries@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated $3.4 million in sales of goods & services in FY 2022.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.